Literature DB >> 1421396

Response of human platelets to activating monoclonal antibodies: importance of Fc gamma RII (CD32) phenotype and level of expression.

Y Tomiyama1, T J Kunicki, T F Zipf, S B Ford, R H Aster.   

Abstract

Certain monoclonal antibodies (MoAbs) specific for platelet membrane glycoproteins are known to be capable of activating platelets, and it is generally thought that platelets from normal subjects are equally susceptible to stimulation by such MoAbs. We found that platelets from 20 normal donors varied significantly in their sensitivity to three IgG1 murine MoAbs specific for membrane glycoproteins CD9, GPIV (CD36), and the GPIIb/IIIa complex (CD41), respectively. The response of platelets to these MoAbs was blocked by prior addition of MoAb IV.3 specific for the Fc gamma RII receptor, indicating that activation was Fc receptor mediated. Platelets that responded poorly to these MoAbs failed to bind the MoAb 41H.16, specific for the "responder" form of Fc gamma RII, but platelets that responded well reacted with this MoAb. The average number of Fc gamma RII receptors on platelets from "responders" and "non-responders" was approximately the same. However, the number of Fc gamma RII receptors expressed influenced sensitivity of a subgroup of "responder" platelets to the anti-CD41 MoAb. These platelets were judged on the basis of MoAb binding studies to be heterozygous for the two alleles of Fc gamma RIIA. In contrast to their varying sensitivity to IgG1 MoAbs, members of the platelet panel responded equally well to 50H.19, an IgG2a MoAb specific for CD9, and these responses could not be blocked by MoAb IV.3 in the presence of plasma. This appears to be because of dual actions of 50H.19 on platelets: one FcR-dependent and the other complement-dependent. Our findings confirm previous reports that certain IgG1 MoAbs activate platelets through binding of their Fc domains to Fc gamma RII receptors and demonstrate that this response is influenced both by Fc gamma RII phenotype and (in the case of the anti-CD41 MoAb) by the number of Fc gamma RII receptors expressed. The failure of nonresponding platelets to bind detectable amounts of MoAb 41H.16, which is thought to recognize all Fc gamma RII receptors except for one allele of the Fc gamma RIIA gene, is consistent with the possibility that Fc gamma RIIA gene products, but not Fc gamma RIIB or Fc gamma RIIC gene products, are expressed on platelets.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1421396

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  19 in total

1.  TC21/RRas2 regulates glycoprotein VI-FcRγ-mediated platelet activation and thrombus stability.

Authors:  S Janapati; J Wurtzel; C Dangelmaier; B K Manne; D Bhavanasi; J C Kostyak; S Kim; M Holinstat; S P Kunapuli; L E Goldfinger
Journal:  J Thromb Haemost       Date:  2018-06-08       Impact factor: 5.824

2.  Transmembrane 4 superfamily protein CD151 (PETA-3) associates with beta 1 and alpha IIb beta 3 integrins in haemopoietic cell lines and modulates cell-cell adhesion.

Authors:  S Fitter; P M Sincock; C N Jolliffe; L K Ashman
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

3.  Genetic diversity in human Fc receptor II for immunoglobulin G: Fc gamma receptor IIA ligand-binding polymorphism.

Authors:  A F Reilly; C F Norris; S Surrey; F J Bruchak; E F Rappaport; E Schwartz; S E McKenzie
Journal:  Clin Diagn Lab Immunol       Date:  1994-11

4.  CalDAG-GEFI deficiency protects mice in a novel model of Fcγ RIIA-mediated thrombosis and thrombocytopenia.

Authors:  Moritz Stolla; Lucia Stefanini; Pierrette André; Timothy D Ouellette; Michael P Reilly; Steven E McKenzie; Wolfgang Bergmeier
Journal:  Blood       Date:  2011-06-07       Impact factor: 22.113

5.  Anti-vWf antibodies induce GPIbalpha and FcgammaRII mediated platelet aggregation only at low shear forces.

Authors:  M F Hoylaerts; A Viaene; C Thys; H Deckmyn; J Vermylen
Journal:  J Thromb Thrombolysis       Date:  2001-12       Impact factor: 2.300

6.  PRT-060318, a novel Syk inhibitor, prevents heparin-induced thrombocytopenia and thrombosis in a transgenic mouse model.

Authors:  Michael P Reilly; Uma Sinha; Pierrette André; Scott M Taylor; Yvonne Pak; Francis R Deguzman; Nisha Nanda; Anjali Pandey; Moritz Stolla; Wolfgang Bergmeier; Steven E McKenzie
Journal:  Blood       Date:  2010-11-18       Impact factor: 22.113

7.  Mechanisms of platelet activation by a stimulatory antibody: cross-linking of a novel platelet receptor for monoclonal antibody F11 with the Fc gamma RII receptor.

Authors:  U P Naik; Y H Ehrlich; E Kornecki
Journal:  Biochem J       Date:  1995-08-15       Impact factor: 3.857

8.  Inhibitory FcγRIIb-Mediated Soluble Antigen Clearance from Plasma by a pH-Dependent Antigen-Binding Antibody and Its Enhancement by Fc Engineering.

Authors:  Yuki Iwayanagi; Tomoyuki Igawa; Atsuhiko Maeda; Kenta Haraya; Naoko A Wada; Norihito Shibahara; Ken Ohmine; Takeru Nambu; Genki Nakamura; Futa Mimoto; Hitoshi Katada; Shunsuke Ito; Tatsuhiko Tachibana; Kou-ichi Jishage; Kunihiro Hattori
Journal:  J Immunol       Date:  2015-08-28       Impact factor: 5.422

9.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

10.  Identification of FcgammaRIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets.

Authors:  Brian Boylan; Cunji Gao; Vipul Rathore; Joan C Gill; Debra K Newman; Peter J Newman
Journal:  Blood       Date:  2008-07-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.